Richard Greil

Research.com Recognitions

• Member of the European Academy of Sciences and Arts
• Member of the European Academy of Sciences and Arts

Overview

Best Publications

• Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048) : a randomised, open-label, phase 3 study

  Barbara Burtness;Kevin J. Harrington;Richard Greil;Denis Soulières

  2608
  Citations

• Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial

  Raimund Jakesz;Walter Jonat;Michael Gnant;Martina Mittlboeck

  1249
  Citations

• Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial

  Andreas Engert;Heinz Haverkamp;Carsten Kobe;Jana Markova

  752
  Citations

• Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial

  Carol Moreno;Richard Greil;Fatih Demirkan;Alessandra Tedeschi

  577
  Citations

• Intensified Chemotherapy and Dose-Reduced Involved-Field Radiotherapy in Patients With Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD11 Trial

  Hans Theodor Eich;Volker Diehl;Helen Görgen;Thomas Pabst

  525
  Citations

• Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone

  M. Gnant;M. Filipits;R. Greil;H. Stoeger

  444
  Citations

• Randomized Phase II Study of the Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer

  José Baselga;Patricia Gómez;Richard Greil;Sofia Braga

  424
  Citations

• Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial.

  Vivek Subbiah;Ulrik Lassen;Elena Élez;Antoine Italiano

  402
  Citations

• The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2− breast cancer patients

  P Dubsky;J C Brase;R Jakesz;M Rudas

  395
  Citations

• PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group.

  Peter Borchmann;Helen Goergen;Carsten Kobe;Andreas Lohri

  380
  Citations

• AVEREL: A Randomized Phase III Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER2-Positive Locally Recurrent/Metastatic Breast Cancer

  Luca Gianni;Gilles H. Romieu;Michail Lichinitser;Sergio V. Serrano

  337
  Citations

• Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12

  M. Gnant;B. Mlineritsch;H. Stoeger;G. Luschin-Ebengreuth

  335
  Citations

• T cells in multiple myeloma display features of exhaustion and senescence at the tumor site

  Claudia Zelle-Rieser;Shanmugapriya Thangavadivel;Rainer Biedermann;Andrea Brunner

  320
  Citations

• Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial.

  Florence Ader;Maude Bouscambert-Duchamp;Maya Hites;Nathan Peiffer-Smadja;Nathan Peiffer-Smadja

  319
  Citations

• Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study

  Andreas Tiede;Robert Klamroth;Rüdiger E. Scharf;Ralf U. Trappe

  288
  Citations

• Drug-induced Apoptosis Is Associated with Enhanced Fas (Apo-1/CD95) Ligand Expression but Occurs Independently of Fas (Apo-1/CD95) Signaling in Human T-Acute Lymphatic Leukemia Cells

  Andreas Villunger;Alexander Egle;Marion Kos;Bernd L. Hartmann

  270
  Citations

• Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD.

  Richard F. Schlenk;Richard F. Schlenk;Daniela Weber;Walter Fiedler;Helmut R. Salih

  265
  Citations

• Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study

  Heinz Gisslinger;Christoph Klade;Pencho Georgiev;Dorota Krochmalczyk

  259
  Citations

• The PAM50 Risk-of-Recurrence Score Predicts Risk for Late Distant Recurrence after Endocrine Therapy in Postmenopausal Women with Endocrine-Responsive Early Breast Cancer

  Martin Filipits;Torsten O. Nielsen;Margaretha Rudas;Richard Greil

  250
  Citations

• Impact of Body Mass Index on the Efficacy of Endocrine Therapy in Premenopausal Patients With Breast Cancer: An Analysis of the Prospective ABCSG-12 Trial

  Georg Pfeiler;Robert Königsberg;Christian Fesl;Brigitte Mlineritsch

  248
  Citations